Goldman Sachs analyst Matthew Sykes raised the firm’s price target on Cytek Biosciences (CTKB) to $5.25 from $4.50 and keeps a Sell rating on the shares. The firm corrected an error to the company’s model following its double downgrade to Sell on Friday, as it did not include Cytek’s marketable securities in the total cash number. Including marketable securities into the total cash balance ups the price target to $5.25.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences downgraded to Sell from Buy at Goldman Sachs
- Big banks report Q4 beats, QXO proposes to buy Beacon: Morning Buzz
- Morning Movers: Wells Fargo and Citi gain following Q4 earnings
- Cytek Biosciences sees Q4 revenue $57M-$58M, consensus $61.49M
- Cytek Biosciences sees FY24 revenue $200M-$201M, consensus $204.71M